Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease

After more than 50 years of treating Parkinson’s disease with l-DOPA, there are still no guidelines on setting the optimal dose for a given patient. The dopamine transporter type 1, now known as solute carrier family 6 (neurotransmitter transporter), member 3 (SLC6A3) is the most powerful determinan...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Brain
Main Authors: Moreau, Caroline, Meguig, Sayah, Corvol, Jean-Christophe, Labreuche, Julien, Vasseur, Francis, Duhamel, Alain, Delval, Arnaud, Bardyn, Thomas, Devedjian, Jean-Christophe, Rouaix, Nathalie, Petyt, Gregory, Brefel-Courbon, Christine, Ory-Magne, Fabienne, Guehl, Dominique, Eusebio, Alexandre, Fraix, Valérie, Saulnier, Pierre-Jean, Lagha-Boukbiza, Ouhaid, Durif, Frank, Faighel, Mirela, Giordana, Caroline, Drapier, Sophie, Maltête, David, Tranchant, Christine, Houeto, Jean-Luc, Debû, Bettina, Azulay, Jean-Philippe, Tison, François, Destée, Alain, Vidailhet, Marie, Rascol, Olivier, Dujardin, Kathy, Defebvre, Luc, Bordet, Régis, Sablonnière, Bernard, Devos, David
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2015
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963414/
https://ncbi.nlm.nih.gov/pubmed/25805645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awv063
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares